Bellevue Life Sciences Acquisition Corp. (BLACU) Prices $60M IPO
Bellevue Life Sciences Acquisition Corp. priced its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “BLACU” Friday, February 10, 2023.
The new SPAC intends to acquire a target business in the healthcare industry, specifically in the biotechnology sector developing the next generation of biologics. Bellevue Life Sciences is led by CEO Kuk Hyuon Hwang, CFO David J. Yoo, and Nominee for Chairman of the Board Steven Reed.
Total SPAC deal count for 2023 year-to-date is now 4. This offering is expected to close on Tuesday, February 14.
Chardan is acting as the sole book-running manager of the offering. K&L Gates LLP is serving as Issuer’s Counsel with Kirkland & Ellis LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.